

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Atogepant for preventing migraine [ID5090]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes. The consultation comments highlighted that migraine can be classed as a disability under the Equality Act 2010, and that because migraine is most common in people of working age and affects more women than men, women may be further disadvantaged in the workplace. It was also noted that there may be issues accessing treatments and availability of specialist care.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal. The committee will be made aware of issues related to ease of access to treatment and specialist care in relation to people with migraine.

Migraine as a disability can be considered by the committee, if appropriate, at the time of the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): ...Jasdeep Hayre

Date: 18/01/2023